Project Grant R01AG098158
- Federal Project Grant Award Summary Fox Chase Chemical Diversity Center Inc. received a $1,074,362 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded March 1, 2026, with completion targeted for November 30, 2030. The award supports AI-driven discovery of in vivo chemical probes for understudied protein targets relevant to Alzheimer's Disease and Related Dementias (ADRD) treatment. The center will systematically evaluate approximately 15...
- Federal Project Grant Award Summary Baylor College of Medicine received a $3,039,032 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on August 15, 2025, with a completion date of July 31, 2029. The grant funds research investigating the relationship between SARS-CoV-2 (COVID-19) infection and the initiation and acceleration of Alzheimer's disease and related dementias (AD/RD), including Pick's disease, frontotemporal dementia, and other...
- Federal Project Grant Award Summary S-3 Research LLC received a $999,556 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 20, 2025, with completion targeted for September 19, 2026. The award supports development of a multi-modal digital tool designed to improve diversity and inclusion in Alzheimer's Disease and Related Dementias (ADRD) clinical trial participation. The deliverables include a trial matching algorithm specific...
- Federal Project Grant Award Summary Emory University received a $528,876 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective June 1, 2025 through March 31, 2030. This award supports the development and application of novel analytical tools to investigate cis- and trans-genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias (AD/ADRD). The research extends current...
- Federal Grant Award Summary The National Institute on Aging awarded Columbia University's Health Sciences Division a $6.9 million Project Grant under the Aging Research program (CFDA 93.866) to develop a Multi-Organ AI-Derived Endophenotype (MAE) framework for personalized assessment of Alzheimer's disease and related dementia susceptibility. The grant, effective August 1, 2025 through July 31, 2029, supports the creation of computational diagnostic and prognostic tools by consolidating and...
- Federal Project Grant Award Summary Duke University's Office of Research Administration is conducting a five-year research project funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), with $493,972 obligated for the project period spanning January 1, 2026, through December 31, 2030. The project, titled "Cell Type-Specific Epitranscriptomic Regulation in the Brain in Aging and Alzheimer's Disease," focuses on understanding how adenosine methylation...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $1,450,964 Project Grant to The Regents of the University of California, Berkeley, under the Aging Research program (CFDA 93.866) to develop novel statistical methodologies for understanding heterogeneous causal pathophysiology of Alzheimer's disease (AD). The award, issued May 15, 2025, with completion targeted for February 28, 2030, addresses a critical gap in understanding how and when amyloid-beta-lowering...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $610,836 Project Grant to the Broad Institute of MIT and Harvard, effective September 1, 2025, through May 31, 2030, under the Aging Research program (CFDA 93.866). This award supports systematic investigation of mitonuclear genetic interactions—the complex interplay between mitochondrial DNA (mtDNA) and nuclear genome regulation—and their contribution to aging and age-related neurodegenerative diseases,...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded the University of Washington a $3.08 million Project Grant on September 1, 2025, through the Aging Research program (CFDA 93.866) to develop advanced computational methods and connectome-based biomarkers for early detection of Alzheimer's disease and related dementias (ADRD). The four-year project, extending through August 31, 2029, addresses critical limitations in current diagnostic approaches by leveraging...
- Federal Grant Award Summary J. David Gladstone Institutes received a Project Grant award of $817,357 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective June 15, 2025, with a completion date of March 31, 2030. The award supports research applying novel machine learning (ML) approaches to behavioral analysis and brain signal integration in humanized Alzheimer's disease (AD) models. The primary deliverable involves validation and development of a...
Award Details: National Institute on Aging (NIA) | Aging Research Program (CFDA 93.866) | $1,343,997 | Award Date: March 1, 2026 | Performance Period: March 1, 2026 – February 28, 2031 Baylor College of Medicine's Center for Drug Discovery will generate tool compounds and chemical probes targeting putative Alzheimer's disease (AD) and AD-related dementias therapeutic targets using DNA-encoded libraries (DELs) integrated with machine learning (ML) methodologies. The project encompasses three primary deliverables: (1) DEL screening against dozens of AD/ADRD targets, with public release of the OpenDEL library (907 million chemical structures), selection input/output datasets, synthesized and validated hits, and optimized tool compounds; (2) in-depth hit-to-lead optimization for select targets chosen in consultation with a Target Advisory Board; and (3) development of DEL-ML predictive models trained on selection datasets to identify candidate binders in virtual re-purposing libraries of Phase I investigational drugs, with biochemical validation and potential fast-track advancement to animal and clinical testing. The project emphasizes scientific resource-sharing and collaborative advancement of AD drug discovery through public release of compounds, datasets, and trained ML models, positioning the outputs to accelerate methodology development and therapeutic candidate identification across the research and development community. The five-year initiative combines the institution's pre-existing DEL capabilities with computational approaches to identify novel therapeutics while simultaneously enabling broader access to integrated chemical and machine learning tools for AD/ADRD research.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 2/27/26 |